Capricor Therapeutics, Inc. (CAPR) — 8-K Filings

8-K Filings (21)

• 8-K Filing — Dec 5, 2025
• Capricor Therapeutics Files 8-K — Dec 3, 2025 Risk: low
  On December 3, 2025, Capricor Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events a
• Capricor Therapeutics Files 8-K Report — Jul 11, 2025 Risk: low
  On July 11, 2025, Capricor Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits, in
• Capricor Therapeutics Appoints MIT Professor to Board — May 27, 2025 Risk: low
  Capricor Therapeutics, Inc. announced on May 22, 2025, the appointment of Dr. Linda T. Griffith to its Board of Directors. Dr. Griffith is a distinguished profe
• Capricor Therapeutics Files 8-K on Operations — May 13, 2025 Risk: low
  On May 13, 2025, Capricor Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as
• Capricor Therapeutics Appoints New Chief Medical Officer — Apr 8, 2025 Risk: medium
  Capricor Therapeutics, Inc. announced on April 8, 2025, the appointment of Dr. Linda D. Smith as its new Chief Medical Officer. Dr. Smith, previously a Senior V
• Capricor Therapeutics Files 8-K — Mar 19, 2025 Risk: low
  Capricor Therapeutics, Inc. filed an 8-K on March 19, 2025, reporting on its results of operations and financial condition, as well as financial statements and
• Capricor Therapeutics Files 8-K — Mar 4, 2025 Risk: low
  On March 4, 2025, Capricor Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine disclos
• Capricor Therapeutics Files 8-K — Jan 2, 2025 Risk: low
  On January 2, 2025, Capricor Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no speci
• Capricor Therapeutics Files 8-K on Financials — Nov 13, 2024 Risk: low
  On November 13, 2024, Capricor Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition
• Capricor Therapeutics Files 8-K: Material Agreement — Oct 17, 2024 Risk: medium
  On October 16, 2024, Capricor Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Financial S
• Capricor Therapeutics Closes $100M Public Offering — Oct 16, 2024 Risk: medium
  On October 16, 2024, Capricor Therapeutics, Inc. announced the closing of its previously announced underwritten public offering. The company successfully raised
• Capricor Therapeutics Completes Enrollment in Phase 3 DMD Trial — Oct 9, 2024 Risk: medium
  On October 9, 2024, Capricor Therapeutics, Inc. filed an 8-K to report on the status of its lead product candidate, CAP-1002. The company announced that it has
• Capricor Sells Ex-US CAP-1002 Rights to Sarepta for $100M — Sep 24, 2024 Risk: medium
  Capricor Therapeutics, Inc. announced on September 24, 2024, that it has entered into a definitive agreement to sell its ex-US rights to its Duchenne muscular d
• Capricor Therapeutics Files 8-K: Material Agreement & Equity Sales — Sep 17, 2024 Risk: medium
  On September 16, 2024, Capricor Therapeutics, Inc. entered into a Material Definitive Agreement. The company also disclosed unregistered sales of equity securit
• Capricor Therapeutics Files 8-K on Financials — Aug 7, 2024 Risk: low
  Capricor Therapeutics, Inc. filed an 8-K on August 7, 2024, reporting on its results of operations and financial condition. The filing includes financial statem
• Capricor Therapeutics Files 8-K on Shareholder Vote Matters — May 15, 2024 Risk: low
  Capricor Therapeutics, Inc. filed an 8-K on May 15, 2024, reporting on a submission of matters to a vote of security holders. The filing date is May 15, 2024, w
• Capricor Therapeutics Files 8-K on Financials — May 13, 2024 Risk: low
  On May 13, 2024, Capricor Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The company, incorporated in Delaware, is invol
• Capricor Therapeutics Enters Acquisition Term Sheet — Apr 29, 2024 Risk: medium
  Capricor Therapeutics, Inc. announced on April 29, 2024, that it has entered into a binding term sheet with an unaffiliated third party for a potential acquisit
• Capricor Therapeutics Files 8-K on Financial Condition — Feb 29, 2024 Risk: low
  CAPRICOR THERAPEUTICS, INC. filed an 8-K on February 29, 2024, reporting on its Results of Operations and Financial Condition, as well as Financial Statements a
• Capricor Therapeutics Relocates HQ to San Diego — Jan 11, 2024
  Capricor Therapeutics, Inc. filed an 8-K on January 11, 2024, to update its principal executive offices from Beverly Hills, CA to 10865 Road to the Cure, Suite

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX